SCYX - speculative catalyst playSCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fu
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.465 USD
−21.29 M USD
3.75 M USD
37.12 M
About SCYNEXIS, Inc.
Sector
Industry
CEO
David Angulo Gonzalez
Website
Headquarters
Jersey City
Founded
1999
FIGI
BBG00JVXHBJ8
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Biotech highlight: SCYNEXIS (SCYX)Back to back announcements of good news.
This is a relatively new one for me in this space, but the news (in links below) of the NIH grant followed by the FDA approval of an additional indication will make following today's stock-price-action of interest!
www.scynexis.com
www.scynexis.com
(NOTE: NO
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANSCYX: Scynexis
2022-02-10 07:36:33
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
$SCYX entry PT 6-6.71 Long term PT 18 and higherScynexis to Initiate a Phase 3 Study of Oral Ibrexafungerp as a Step-Down Treatment for Invasive Candidiasis Following Meeting With FDA
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate,
SCYNEXIS Announces Positive Results from Interim Analyses of OngSCYX: Scynexis
2021-03-02 07:30:00
SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
SCYX Long. Bullish Descending WedgeSCYX has been consolidating into this bullish wedge for months now. With upcoming catalysts, such as the first FDA approval for their ibrexafungerp antifungal in Q1 2021 and other catalyst announcements potentially in Q4 2020, this looks prime for a large break out over $10.
I will be buying at an
Technical analysis on SCYXNASDAQ:SCYX
Big picture: it is currently in uptrend channel. Higher highs and lower lows, tightening pattern.
Smaller picture, its underneath EMAs, so that's a bit concerning. But volume looks to be increasing more steadily.
A bit of fundamental analysis, the results from one late stage study sh
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of 0L49 is 0.930 USD — it has decreased by −1.69% in the past 24 hours. Watch SCYNEXIS INC COM USD0.001(POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange SCYNEXIS INC COM USD0.001(POST REV SPLIT) stocks are traded under the ticker 0L49.
0L49 stock has risen by 5.22% compared to the previous week, the month change is a −4.72% fall, over the last year SCYNEXIS INC COM USD0.001(POST REV SPLIT) has showed a −33.49% decrease.
We've gathered analysts' opinions on SCYNEXIS INC COM USD0.001(POST REV SPLIT) future price: according to them, 0L49 price has a max estimate of 7.00 USD and a min estimate of 4.00 USD. Watch 0L49 chart and read a more detailed SCYNEXIS INC COM USD0.001(POST REV SPLIT) stock forecast: see what analysts think of SCYNEXIS INC COM USD0.001(POST REV SPLIT) and suggest that you do with its stocks.
0L49 reached its all-time high on Jan 29, 2018 with the price of 19.000 USD, and its all-time low was 0.760 USD and was reached on Apr 7, 2025. View more price dynamics on 0L49 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0L49 stock is 2.42% volatile and has beta coefficient of 1.56. Track SCYNEXIS INC COM USD0.001(POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is SCYNEXIS INC COM USD0.001(POST REV SPLIT) there?
Today SCYNEXIS INC COM USD0.001(POST REV SPLIT) has the market capitalization of 35.25 M, it has increased by 6.39% over the last week.
Yes, you can track SCYNEXIS INC COM USD0.001(POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
SCYNEXIS INC COM USD0.001(POST REV SPLIT) is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
0L49 earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.02 USD resulting in a −350.00% surprise. The estimated earnings for the next quarter are −0.19 USD per share. See more details about SCYNEXIS INC COM USD0.001(POST REV SPLIT) earnings.
SCYNEXIS INC COM USD0.001(POST REV SPLIT) revenue for the last quarter amounts to 977.00 K USD, despite the estimated figure of 10.19 M USD. In the next quarter, revenue is expected to reach 137.00 K USD.
0L49 net income for the last quarter is −4.43 M USD, while the quarter before that showed −2.81 M USD of net income which accounts for −57.87% change. Track more SCYNEXIS INC COM USD0.001(POST REV SPLIT) financial stats to get the full picture.
No, 0L49 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 21, 2025, the company has 28 employees. See our rating of the largest employees — is SCYNEXIS INC COM USD0.001(POST REV SPLIT) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SCYNEXIS INC COM USD0.001(POST REV SPLIT) EBITDA is −37.12 M USD, and current EBITDA margin is −990.84%. See more stats in SCYNEXIS INC COM USD0.001(POST REV SPLIT) financial statements.
Like other stocks, 0L49 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SCYNEXIS INC COM USD0.001(POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SCYNEXIS INC COM USD0.001(POST REV SPLIT) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SCYNEXIS INC COM USD0.001(POST REV SPLIT) stock shows the sell signal. See more of SCYNEXIS INC COM USD0.001(POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.